nosis with standard chemotherapy. Allogeneic bone marrow transplantation (BMT) in remission improves the outlook only for the one third of patients with sibling donors. Autologous BMT with a lower morbidity and mortality is available to all. In this study, maximum cytoreduction was achieved by intensive early chemotherapy. Final intensification, with autologous BMT was offered to all those remaining in first complete remission (CR). Patients received two induction and two consolidation courses of intensively scheduled chemotherapy. Cytoreduction was assessed on day 14 and remission was assessed after courses 2 and 4. Bone marrow was harvested after recovery from the second consolidation course or after the first maintenance course and separated on a discontinuous percoll gradient before cryopreservation. Twenty-eight of 31 consecutively enrolled patients achieved CR. Three relapsed early and, of the 25 eligible, 24 underwent autologous BMT. Twenty-three patients received high-dose mel-
ESPITE IMPROVEMENTS in remission induction
D rates, the prognosis of children with acute myeloid leukemia (AML) treated with chemotherapy in the early 1980s remained poor. The most successful chemotherapeutic regimens, reported by Weinstein et al' and Creutzig et al,' involved cyclic myelosuppressive therapy for periods of 1 to 2 years and resulted in continuous complete remission rates (CR) of approximately 50% at 5 years, with event-free survival (EFS) being approximately 40% at 5 years.
Allogeneic bone marrow transplantion (BMT) performed in first remission has produced posttransplant disease-free survival rates of 50% to 6596, with relapse rates as low as 8% to 20%.*6 Transplant-related morbidity and mortality were considerable, although lower in young patients, resulting in more favorable outcome after allogeneic BMT in children and young First remission allogeneic BMT is regarded by some as the treatment of choice for young patients with AML who have an HLA-compatible Only 30% of patients with AML who achieve CR will have a suitably matched donor. Autologous BMT, initially studied in patients who had relapsed and subsequently in patients in first remission, extends the potential benefits of to 301) after initial CR. Trilineage engraftment occurred in all. Neutrophil recovery to greater than 0.5 X 10s/L occurred at a median of 46 days (range, 13 to 92) after autologous BMT. Platelet recovery was delayed, with a median time to achieve greater than 20 X 1 Os/L of 42 days (range, 1 8 to 21 5). With a minimum follow up of 25 months following autologous BMT only 3 children have relapsed. The 5-year event-free survival rate (EFS) from diagnosis is 68% (95% confidence interval, 46% to 90%). Five-year EFS following autologous BMT is 87% (95% confidence interval, 67% to 100%). Autologous BMT with high-dose melphalan administration after intensive chemotherapy has produced EFS equivalent to allogeneic BMT and is associated with a strikingly low relapse rate. High-dose melphalan appears to be a valuable agent for conditioning therapy in AML.
0 1993 by The American Society of Hematology.
"megadose" therapy to those who have no donor. Early results showed that remissions could be induced in those in relapse. Patients undergoing autologous BMT in CR after a variety of conditioning regimens had posttransplant relapse-free rates ranging from 22% to 75% with variable follow-up period^.^-'^ Attempts to reduce the 25% to 62% relapse rates by in vitro purging showed that, whereas purging did not interfere with engraftment, its role in reducing relapse rates was more difficult to demonstrate. '"16 None of the previously reported studies of autologous BMT in AML patients deals exclusively with a population of children treated uniformly from diagnosis to transplantation. We report the results ofa therapeutic regimen designed to give intensive initial therapy to children newly diagnosed with AML, followed by autologous BMT using melphalan for conditioning. Five years from diagnosis the EFS rate is 68%. After autologous BMT, the EFS rate is 87% at 5 years.
MATERIALS AND METHODS

Treatment Protocol
A protocol for the treatment of all previously untreated children with AML was developed based on our previous chemotherapy experience and a review of the then available literature, which showed equivalent overall survival for patients receiving allogeneic or autologous BMT.","
The treatment protocol is shown in Table 1 . A bone marrow aspirate was performed on day 14 to assess cytoreduction. If the marrow was hypocellular but contained greater than 5% blasts, course two consisted of cytosine arabinoside (Ara-C) 2 g/m2 intravenous (IV) infusion over 3 hours, 12 hourly X 6 doses commencing immediately. If the marrow remained hypercellular with persisting blasts, Ara-C was given in a dose of 3 g/m2, 12 hourly X I O doses. Course two was delayed until early signs of marrow recovery appeared if the marrow was hypocellular with fewer than 5% blasts identified. If a delay of greater than 1 week occurred without evidence of early hematologic recovery, the marrow aspirate was re- peated to ensure that there was no repopulation with blasts. Remission status was determined after recovery from myelosuppression following the second induction course. Two courses of consolidation therapy were then given to patients in CR. Patients not in CR were withdrawn from study. Remission status was again confirmed by bone marrow aspirate at the end of consolidation therapy.
Preventative CNS therapy was given to all patients with age-related intrathecal methotrexate (IT MTX) administered with each systemic course of treatment during induction and consolidation, followed by four doses at weekly intervals on completion of the consolidation phase oftherapy. No additional systemic or local therapy was given to patients with extramedullary disease at diagnosis.
Maintenance therapy consisted of 5-day courses of Ara-C and 6-thioguanine monthly until autologous BMT, with the intent of giving not more than 2 to 3 courses.
Conditioning therapy for autologous BMT was with melphalan in a dose of 140 mg/m2 in 2 patients and 180 mg/m2 in 21 patients, administered by infusion over 15 minutes through a central venous catheter. This drug was unavailable in IV formulation for 1 patient who received busulphan (16 mg/kg) and cyclophosphamide (120 The protocol was approved by the Human Ethics Committee. All families were HLA typed after remission was achieved to determine the availability of an HLA-matched sibling. Families were advised that the survival of autologous and allogeneic BMT were similar and that we were investigating the role of autologous BMT. They mg/kg).
were informed that if the patient relapsed following autologous BMT, then those who had a sibling donor would have an allogeneic BMT. Informed consent was obtained for the procedure of bone marrow harvesting and autologous BMT.
Pat ients
Of 34 consecutively diagnosed children with AML, 3 1 were entered into the study between November 1984 and January 1991. One child with Down's syndrome and two children with preleukemic myelodysplasia were excluded. All families and, when appropriate, patients agreed to participate in this study. Specifically, none requested an allogeneic BMT in first CR. The results were analysed as of June 1993 giving a minimum follow-up of 2% years.
The diagnosis and subgroup classification of AML was based on the criteria of the French, American, British (FAB) cooperative group." Banded cytogenetic studies were routinely performed on the diagnostic marrow and on the marrow aspirate obtained after completion of consolidation therapy.
Response Criteria
CR was defined as the disappearance of clinical evidence of leukemia and a normocellular marrow showing maturation of all cell lines, fewer than 5% blast cells, and no Auer rods. Relapse was defined as the presence ofgreater than 5% blasts in the bone marrow or the presence of extramedullary disease.
Supportive Care
Patients were nursed in single rooms or laminar air-flow beds during the periods of pancytopenia associated with induction therapy and after autologous BMT. Trimethoprim-sulphamethoxazole prophylaxis was administered during induction therapy and after transplantation once granulocyte engraftment had occurred. All patients had indwelling central venous catheters during the transplant phase, but these were not used routinely in the early years of the study during the induction and consolidation phases. Episodes of fever associated with neutropenia were treated with broad-spectrum antibiotics, antifungal agents being added if fever persisted or there was clinical suspicion of fungal sepsis.
Random donor irradiated platelets were given to maintain platelet counts above 20 X 109/L during induction and the posttransplant phase, and at other times as required. Parenteral nutrition (TPN) was used as required during induction and the posttransplant phase.
Bone Marrow Harvest, Separation, and Storage
Marrow harvests were performed under general anesthesia. A volume of 15 to 20 mL/kg was aspirated from the iliac crests and placed into heparinised Hanks' Balanced Salt Solution (HBSS), filtered through 0.3 mm mesh, centrifuged at 850g, and the bu& coat harvested and layered onto a discontinuous percoll gradient for separation and stem cell enrichmer~t.l~*~~ The fraction separating at the 50%:60% percoll interface was collected and washed, 10% dimethyl sulfoxide (DMSO) and 20% fetal calf serum (FCS) added as a cryopreservant, and stored in 5 mL ampoules at -196°C in liquid nitrogen after rate controlled freezing.
Before administration, the bone marrow was thawed in a waterbath at 42"C, diluted 1:2 with HBSS, I mg DNase added, and rapidly reinfused.
In 13 patients whose harvest yielded more than 4 X 108/kg nucleated marrow cells with postpercoll recovery of 10% or greater, an aliquot ofmarrow (minimum 0.12 X lO*/kgnucleated, percoll separated cells) was stored for use in the event of relapse.
For
Statistical Analysis
All patients were assessed for initial response to treatment (CR rate). Event-free survival (EFS), overall survival and postautologous BMT EFS were calculated by the product limit estimates of Kaplan and Meier.*' Events were defined as failure to achieve initial remission, relapse, or death from any cause.
RESULTS
Patient Characteristics
The clinical and laboratory features of all patients at diagnosis are listed in Table 2 . There were 17 male and 14 female patients whose ages ranged from 3 months to 16 years (median, 7 years). Patients older than 16 years were not admitted to our hospital.
Two children, both with initial white blood cell count (WCC) >lo0 X 109/L had central nervous system (CNS) disease at diagnosis. Three of 5 patients with extramedullary disease at presentation had M4 or M5 morphology. The incidence of extramedullary disease among patients with M4 or M5 morphology was 20% and 12.5% among patients with other morphology.
Banded cytogenetic studies were obtained on diagnostic bone marrows in 30 patients, and showed the expected range of chromosomal abnormalities. Cytogentic studies were repeated on all patients before the marrow harvest, either at the end of consolidation or after one cycle of maintenance, and they were all normal.
Remission Induction and Consolidation
Thirty-one patients were entered on the study. One (patient [pt] no. 22) who presented with a WCC of 320 x 109/L and CNS involvement had a rapidly rising WCC, developed pulmonary infiltrates with associated respiratory failure, and died of cerebral hemorrhage 36 hours after admission. The WCC shortly before death was 700 X 109/L.
Thirty patients completed induction therapy and 28 achieved remission (CR rate 90%). Seventeen patients had fewer than 5% blasts in a hypocellular marrow on D14 and had their second course of therapy delayed by a median of 8 days (range, 0 to 12); all achieved CR after the second induction course. Eleven patients had hypocellular marrows with greater than 5% persisting blasts and all commenced their second course of therapy immediately. On recovery from myelosuppression, I O were in CR, whereas one (pt 15) had persistent disease and was removed from study. Two patients (pts 4 and 28) had persisting hypercellularity with 50% and 99% blasts, respectively, on day 14. Both received the more intensive course ofAra-C. One was in CR on recov- 
28). The other (pt 4) had persistent disease, was taken off study, but did achieve CR after a further course of highdose Ara-C.
Of the 28 patients who completed consolidation, 25 remained in CR and proceeded to maintenance therapy. Three patients (pts 5, 1 I, and 17) were in bone marrow relapse after consolidation, two having had residual blasts in a hypocellular marrow on day 14. Of the 25 patients eligible for autologous marrow transplantation, one (pt 3) refused either autologous or allogeneic transplantation, and continued with cycles of maintenance therapy until relapse 7 months from achieving CR. His day 14 marrow had been hypocellular with persistent blasts.
Bone Marrow Harvest and Autologous BMT
Twenty-four patients had bone marrow harvested at a median of 98 days (range 62 to 300) after achieving CR. The one late harvest was at patient insistence and not for medical indication. The marrow was harvested before maintenance therapy in 8 patients, after 1 to 2 courses of maintenance in 15 and after 6 courses in 1. The median time from documentation of CR to marrow reinfusion was 1 13 days (range, 86 to 301).
The initial 2 autografted patients in the series (pts 1 and 2) received melphalan 140 mg/m2. Patient 13 received busulphan I6 mg/kg and cyclophosphamide 120 mg/kg and the remaining 21 patients received melphalan 180 mg/m2 as conditioning therapy. Marrow was reinfused 1 to 3 days after conditioning. Two patients (pts 1 and 7) had reinfusion of percoll-separated noncryopreserved marrow and the remainder received thawed cryopreserved marrow that had been stored for a median of 7 days (range, 1 to 43). The median viable nucleated cell dose reinfused was 0.33 X lo8/ kg (range, 0.08 to 0.95) and median granulocyte-macrophage colony-forming units (CFU-GM) reinfused was 5.7 X 104/kg (range, 0 to 29.7) Details of hematologic recovery and status after autologous BMT are shown in Table 3 . The range and median time to granulocytes greater than 0.5 X 109/L was 13 to 92 days (median, 46) and to platelet count greater than 20 x 109/L was 18 to 2 15 days (median, 42). There was no correlation between the number of nucleated cells or CFU-GM infused and the time to granulocyte or platelet recovery.
All 24 children who had an autologous BMT regained normal granulocyte counts and became transfusion and platelet independent, although 1 (pt 16) remains mildly thrombocytopenic with a platelet count of 125 X 109/L, 4.9 years after transplantation.
Toxicity
All children were hospitalized for induction therapy and for each consolidation course of therapy. Maintenance courses were given on an ambulatory basis. All 30 patients evaluable for toxicity during induction developed grade 4 neutropenia and thrombocytopenia. All required red blood cell and platelet support. Twenty nine (97%) became febrile while neutropenic and received broad spectrum antibiotics, and 2 received amphoInduction and consolidation. 1) . All children experienced grade-4 neutropenia and 25 (89%) grade-4 thrombocytopenia after consolidation course two. Twenty-seven (96%) required red blood cell transfusion and 25 (89%) required platelet transfusion. Twenty-seven children required IV antibiotics, with 7 having positive blood cultures ( E coli, 3; various Streptococcus species, 4).
One child (pt 13) developed severe acute encephalopathy after his final dose of IT MTX. Autologous BMT was delayed by l month, during which he made progressive slow recovery. He has residual minor learning disability but neurologic recovery is otherwise complete.
All children developed grade-4 hematologic toxicity following high-dose melphalan. All required blood and platelet support. The median number of units of packed cells transfused was 4 (range, 2 to 13) and median number of platelet units 35 (range, 6 to 66).
The 21 patients receiving melphalan 180 mg/m2 all required antibiotic therapy for a median of 10 days (range, 5 to 22). Ten had grade 3 to 4 mucositis and 18 received TPN for a median of 14 days (range, 5 to 43) either because of mucositis or severe anorexia. The two who received melphalan 140 mg/m2 and the child receiving busulphan-cyclophosphamide conditioning had minimal nonhematologic toxicity and required neither antibiotics nor parenteral nutrition.
Three children had oral swabs positive for herpes simplex at the time of mucositis, and were treated with acyclovir. Four children had positive blood cultures (Group C Streptococcus, S aureus, Streptococcus viridans, and coagulasenegative Staphylococcus). One child developed an E coli urinary tract infection. No hepatic, pulmonary, or neurologic toxicity was observed.
Outcome
Overall, 22 of 3 1 children entered remain alive, with 2 1 in CCR with a median follow up of 57 months (range, 25 to 94) after BMT and 62 months (range, 29 to 103) from diagnosis. The relapse incidence among all patients achieving CR was 26%, (Fig I) , with a 13% relapse incidence after autologous BMT. The 5-year actuarial EFS is 68% (95% CI,
High-dose conditioning chemotherapy.
For personal use only. on September 23, 2017. by guest www.bloodjournal.org Abbreviation: ANC, absolute neutrophil count 46% to 90%) and actuarial survival from diagnosis is 70% (Fig 2) . The 5-year actuarial EFS and DFS after autologous BMT is 87% (95% CI, 71% to 100%). Actuarial 5-year surviva1 after autologous BMT is 92% (95% CI, 76% to 100%) (Fig 3) .
Correlation of relapse with 0 1 4 bone marrow status.
Three of 17 patients (1 8%) with hypocellular bone marrow with less than 5% blasts present on day 14 subsequently relapsed, one at the end of consolidation therapy, and 2 after autologous BMT. Two have died. Four of I I patients (37%) with hypocellular marrows with greater than 5% blasts failed, one failing to achieve remission and 3 relapsing 
MONTHS of autologous BMT (-).
For ( -) from diagnosis of AML.
before autologous BMT. All have died. Of the 2 children with persistently cellular marrows with blasts on day 14, 1 (pt 4) failed to achieve remission after the second induction course and the other (pt 28) subsequently relapsed after autologous BMT and again after allogeneic BMT. Both have died. Overall, 12% of patients with hypocellular bone marrows with less than 5% blasts on day 14, 37% of those with greater than 5% blasts, and 100% of those with cellular bone marrows on day 14 have died of disease.
Patients not in CR after induction therapy. Both children (pts 4 and 15) who failed to remit after the two courses of induction therapy, achieved remission with a further course of high-dose Ara-C 3mg/m2 X 10 doses. Both patients then received consolidation therapy as per this protocol. Patient 4 lacked a sibling donor and was in relapse at the time of planned autologous bone marrow harvest and died 9 months after diagnosis. Patient 15 proceeded to matched sibling donor BMT but relapsed and died 18 months after diagnosis.
The 3 chilPatients relapsing before autologous BMT. 
MONTHS FROM DIAGNOSIS
dren who were in marrow relapse at the end of consolidation therapy (pts 5, 1 1, and 17) failed further chemotherapy and died 6, 6, and 8 months, respectively, after diagnosis.
The patient refusing transplantation relapsed 7 months after achieving CR and died 12 months from diagnosis after only transiently responding to further chemotherapy. Patients relapsing after autologous BMT. All 3 patients relapsing after autologous BMT were successfully reinduced with further chemotherapy. Patient 10 suffered protracted marrow aplasia but recovered and remains in unmaintained, second CR 56 months after relapse. No suitable donor was available for allogeneic BMT and a second autologous BMT was not performed because of the delayed marrow recovery. Patient 3 1, who also had no sibling donor available, relapsed again and died 9 months after autologous BMT. Patient 28 underwent matched sibling allogeneic BMT but subsequently relapsed again and died 24 months after autologous BMT.
The response of all relapsing patients to further therapy, is summarized in Table 4 . 
DISCUSSION
It is generally agreed that early intensive myelosuppressive therapy is necessary to achieve high CR rates in AML patients. Our data support the concept that response to initial therapy is a determinant of eventual outcome: only 3 of 17 patients with hypocellular bone marrow with less than 5% blasts on day 14 relapsed, whereas 4 of 11 with greater than 5% blasts in a hypocellular bone marrow relapsed and both children who failed to show significant cytoreduction on day 14 relapsed and died.
The relative roles of intensive continuation therapy, allogeneic and autologous BMT in children with AML in first CR, remain controversial.2' Recent reports from the Children's Cancer Study Group (CCG, protocol 231) and the German BFM group (AML-BFM, 1983) indicate that a disease-free survival rate of approximately 60% at 3 to 6 years can be achieved with intensive ~hemotherapy.~',~~ Contemporary reports of allogeneic BMT in children and young adults with AML in first CR indicate 5-year disease-free survival rates of43% to 64%.2427
The largest pediatric study, with patients entered at diagnosis, receiving uniform induction therapy and then undergoing a biologic allocation to allogeneic BMT for those with HLA-compatible donors and autologous BMT for those without donors, has been performed by the Children's Cancer Study Group." The actuarial EFS rate 18 months after BMT was 44% for those receiving allogeneic BMT and 54% for patients having autologous BMT, with no significant difference in relapse rates between the groups. The 87% post autologous BMT EFS rate in our series is superior to these results. There appear to be two possible explanations for the better EFS rate of our study.
First, our results indicate that melphalan is an effective conditioning agent when used in first CR. Melphalan was chosen as the conditioning agent when we commenced our autologous BMT program because we had experience with its use in solid tumors, were impressed with its relatively low toxicity, and were keen to avoid the use of total body irradiation in our pediatric population. Its use has been reported as a conditioning agent for both autologous and allogeneic BMT.'2,29 Contrary to our experience, pooled data from the European BMT group suggested that melphalan was less effective than busulphan-cyclophosphamide, or cyclophosphamide and total body irradiation as a conditioning regimen.16 However, these data are difficult to compare with ours because they are derived from multiple institutions, relate predominantly to adults, and no uniform induction-consolidation therapy had been used.
There is some comparative data from the Australian and New Zealand Children's Cancer Study Group, which adopted the same program of induction and consolidation therapy several years after our study commenced. They achieved comparable CR rates, but chose to use allogeneic BMT for patients with HLA-compatible donors and autologous BMT for the remainder. Busulphan and cyclophosphamide (busulphan 16 mg/kg, cyclophosphamide 120 to 200 mg/kg) were used for conditioning for both allogeneic and autologous BMT. Nonfractionated autologous bone marrow was used. Fourteen (42%) of 33 patients receiving transplants with autologous nonfractionated bone marrow relapsed. Only one of 15 patients given an allogeneic BMT relap~ed.~' These preliminary results suggest that, in children, melphalan is more effective than standard dose busulphan and cyclophosphamide in eliminating residual in vivo leukemia. In addition, there may be benefits in separating the marrow on a percoll gradient rather than reinfusing buffy coat or whole bone marrow.
Concern about the risk of reinfusion of leukemic cells in autologous bone marrow has led to varying modalities of in vitro purging, most commonly using cyclophosphamide derivative~.~'"~ Despite many single institutional studies using in vitro purging, the role of purging remains unclear. The European autologous BMT group has recently shown an advantage for purging in patients who received transplants less than 6 months after achieving CR.34 However, early transplantation regimens will include patients who have a potentially greater degree of residual disease, with increased likelihood of early relapse, who would otherwise be excluded from autologous marrow grafting. In vitro purging
For personal use only. on September 23, 2017. by guest www.bloodjournal.org From would be expected to reduce the leukemic burden in this group of patients. Unstable CRs were detected in our study by deferring autologous BMT until after the phase of consolidation, at a median time of 1 13 days after achieving CR.
In our study, no in vitro chemical purging was undertaken. The low post autologous BMT relapse rate of 13.0% is within the range of reported relapse rates after allogeneic BMT in first CR,27 suggesting that, in addition to eliminating unstable CRs, our method of marrow separation and stem cell enrichment may contribute to leukemic cytoreduction. In addition, cryopreservation itself has been reported to have a purging effect.3s Hematologic recovery, particularly of platelet counts, has been delayed in some patients. No life threatening events have occurred, but there has been a requirement for long-term platelet support resulting in platelet refractoriness in some patients. We have not been able to document the development of autoantibodies in these patients, as reported by Minchinton et Delayed hematologic recovery after autologous BMT is a welldocumented p h e n~m e n o n~~,~' and is thought to reflect stem cell loss related to the intensity of chemotherapy before bone marrow harvest. Some further loss of stem cells occurs during the marrow separation procedure. Despite the somewhat delayed recovery, ail children have been in good general health, leading a normal life within 3 months of their autologous BMT without the need for ongoing bloodproduct support. Importantly, all therapy is completed within 5 to 7 months of diagnosis.
This approach has transformed the outcome for our patients with AML, resulting in cure rates equivalent to those for children with acute lymphoblastic leukemia. Previously reported studies indicate that the majority of relapses after autologous BMT occur within 12 months, with relapse after 2 years being u n u~u a l .~'~~~ All surviving patients in this series have follow-up times of more than 2 years and are, therefore, likely to be cured. We conclude that autologous BMT in first CR has low mortality and morbidity and is capable of achieving EFS equivalent or better to that achieved by allogeneic BMT. Conditioning with high-dose melphalan infused over 15 minutes and percoll gradient fractionation of marrow before storage is associated with a strikingly low relapse rate. High-dose melphalan appears to be a valuable agent for conditioning before BMT in AML.
